Cargando…
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy. Therapy with anti-tumor necrosis factor (TNF)-α agents represents the first therapeutic choice for moderate and severe forms; however, PsA patients can experience anti-TNFα failure, lack of efficacy, or adverse events. Several evidence...
Autores principales: | Costa, Luisa, Perricone, Carlo, Chimenti, Maria Sole, Del Puente, Antonio, Caso, Paolo, Peluso, Rosario, Bottiglieri, Paolo, Scarpa, Raffaele, Caso, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694428/ https://www.ncbi.nlm.nih.gov/pubmed/29058302 http://dx.doi.org/10.1007/s40268-017-0215-7 |
Ejemplares similares
-
An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020) -
Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
por: Peluso, Rosario, et al.
Publicado: (2018) -
Simple clinical indicators for early psoriatic arthritis detection
por: Caso, Francesco, et al.
Publicado: (2014) -
Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis
por: Peluso, Rosario, et al.
Publicado: (2019) -
Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future
por: Navarini, Luca, et al.
Publicado: (2020)